New Insights and Promising Ketamine Treatment for Parkinson’s-Related Dyskinesia

Researchers at the University of Arizona have uncovered new insights into levodopa-induced dyskinesia, a common complication of long-term treatment in Parkinson's disease. Parkinson's occurs due to reduced dopamine levels in the brain, and while the drug levodopa helps restore dopamine, extended use often leads to involuntary movements. The study, published in Brain, found that during dyskinesia episodes, the motor cortex, responsible for controlling movement, becomes disconnected rather than actively causing the movements. This challenges previous beliefs about dyskinesia's origins. Using recordings from thousands of neurons, researchers observed minimal correlation between motor cortex activity and the uncontrollable movements, suggesting the movements arise from other neural circuits. The study also highlighted the therapeutic potential of ketamine, an anesthetic. Ketamine disrupts abnormal brain activity during dyskinesia and promotes neuroplasticity, allowing brain cells to form or strengthen connections. A single dose of ketamine showed lasting benefits, with effects persisting for weeks or months. These findings support ongoing clinical trials testing low-dose ketamine infusions for dyskinesia in Parkinson's patients. Researchers hope this work will pave the way for more effective treatments by addressing the underlying mechanisms of dyskinesia.